

QUANTITY LIMIT CRITERIA

BRAND NAME (generic)

LYRICA
(pregabalin)

LYRICA CR
(pregabalin extended-release)

Status: CVS Caremark® Criteria
Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Lyrica

Lyrica is indicated for:

- Management of neuropathic pain associated with diabetic peripheral neuropathy
- Management of postherpetic neuralgia
- Adjunctive therapy for the treatment of partial onset seizures in patients 1 month of age and older
- Management of fibromyalgia
- Management of neuropathic pain associated with spinal cord injury

Lyrica CR

Lyrica CR is indicated for the management of:

- Neuropathic pain associated with diabetic peripheral neuropathy
- Postherpetic neuralgia

Efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

Compendial Uses

Lyrica

- Cancer-Related Neuropathic Pain^{4,5}
- Cancer Treatment-Related Neuropathic Pain^{4,5}

INITIAL LIMIT QUANTITY

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength

Drug	1 Month Limit*	3 Month Limit*
Lyrica (pregabalin) capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg	120 capsules / 25 days	360 capsules / 75 days
Lyrica (pregabalin) capsules 200 mg	90 capsules / 25 days	270 capsules / 75 days
Lyrica (pregabalin) capsules 225 mg, 300 mg	60 capsules / 25 days	180 capsules / 75 days
Lyrica (pregabalin) oral solution 20 mg/mL	900 mL / 25 days	2700 mL / 75 days

Lyrica, Lyrica CR Limit Policy 06-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428B 021423

Lyrica CR (pregabalin extended-release) 82.5 mg	90 tablets / 25 days	270 tablets / 75 days
Lyrica CR (pregabalin extended-release) 165 mg	90 tablets / 25 days	270 tablets / 75 days
Lyrica CR (pregabalin extended-release) 330 mg	60 tablets / 25 days	180 tablets / 75 days

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

REFERENCES

1. Lyrica [package insert]. New York, NY: Parke-Davis; June 2020.
2. Lyrica CR [package insert]. New York, NY: Parke-Davis; June 2020.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed April 22, 2024.
4. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed April 22, 2024.
5. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/22/2024).
6. NCCN Guidelines. Version 2.2024 Adult Cancer Pain. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed April 22, 2024.
7. Fisher RS, Cross JH, French JA, et al. Operational Classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017 Apr;58(4):522-530.